STAT3 and cancer: Relevant to cancers, IL-6 activates STAT3 signaling pathways and high levels of IL-6 is associated with poor prognosis in a variety of cancers such as prostate cancer, bladder cancer, ovarian cancer, colorectal cancer and GC [39,40].